Sector
Healthcare & Sport

Health technologies

The healthcare sector brings together all businesses with a shared objective of promoting access to sustainable healthcare systems for everybody through prevention, diagnosis, overcoming disability and treatment of diseases.
The “Health technologies" sub-sector is covering "Medical devices", "In vitro diagnostic medical devices" and "Health information and data technology".

Examples of partnerships with companies in the sector

Diabeloop and CEA LETI are perfecting insulin delivery by integrating AI into a closed-loop system that alleviates the decision-making burden on patients.

Partnership CEA LETI Carnot Institute - Diabeloop

Researchers and doctors working in a joint research lab have revolutionised the lives of people suffering from Type 1 diabetes. They have moved from one-shot blood sugar measurements and manual insulin injections, with all of the related decision-making and risks, to continuous measurement with personalised, secure insulin delivery.

Close
Partnership CEA LETI Carnot Institute - Diabeloop

Diabeloop and CEA LETI are perfecting insulin delivery by integrating AI into a closed-loop system that alleviates the decision-making burden on patients.

Researchers and doctors working in a joint research lab have revolutionised the lives of people suffering from Type 1 diabetes. They have moved from one-shot blood sugar measurements and manual insulin injections, with all of the related decision-making and risks, to continuous measurement with personalised, secure insulin delivery.

Supporting Innovation

Les conditions de vie des personnes atteintes de diabète insulinodépendant se sont régulièrement améliorées depuis ces 10 dernières années. Du stylo à insuline jusqu’à des dispositifs de mesure en continu de la glycémie avec pompe associée, le suivi de la glycémie et la délivrance d’insuline ont été simplifiés mais dépendent encore largement de multiples prises de décisions du malade. Le risque d’hypoglycémie, notamment nocturne ou consécutif à un effort physique, constitue un souci permanent pour la personne qui vit avec un diabète. Les « systèmes de délivrance automatisée d’insuline » permettent une réelle réduction de la charge mentale quotidienne en toute sécurité. Ainsi le dispositif DBLG1 de Diabeloop régule la délivrance d’insuline en fonction de la mesure continue de glycémie et communique directement avec la pompe via un algorithme hébergé dans un terminal dédié. Des algorithmes calculent en local la quantité d’insuline à injecter, le terminal étant relié par Bluetooth à une pompe patch miniature et à un capteur de glycémie. La charge mentale du patient est ainsi allégée, il lui faut simplement signaler au système ses repas et ses éventuelles activités sportives.

The client needs

Le dérèglement de la production d’insuline caractéristique du diabète de type 1 entraîne de lourdes complications thérapeutiques. Pour les malades souvent diagnostiqués avant 30 ans, c’est une vie de contrôle et suivi pluri-quotidien de la glycémie qui démarre. Dès 2011, l’équipe fondatrice de Diabeloop s’est intéressée à la prévention de l’hypoglycémie et au contrôle glycémique, ainsi qu’aux facteurs d’adoption, par le patient, d’un dispositif de boucle fermée à 3 composants. Constitué d’un système de mesure en continu de la glycémie, d’une pompe à insuline de type patch et d’un algorithme de pilotage, le système doit associer miniaturisation, fiabilisation des mesures, adaptation aux événements et sécurisation des données numériques. Le Carnot CEA LETI, très engagé sur la transition numérique à fort impact sociétal a apporté, dès l’origine, son soutien au projet. Les avancées du dispositif DBLG1 ont porté sur l’algorithme de régulation de l’insuline et pour plus de confidentialité et d’efficacité il fallait que l’algorithme tourne en local sans recourir au cloud mais tout en transmettant en parallèle les données à un service médical de suivi pendant la phase d’essais cliniques.  Le dispositif, déjà certifié CE depuis fin 2018, répond très bien à la réduction des hypoglycémies entre les repas et pendant le jeûne du sommeil. Mais, au-delà, il faut « apprendre » de la vie du malade pour mieux adapter la réponse aux besoins spécifiques du patient et disposer d’un système personnalisé de gestion automatisée de la glycémie ce qui nécessite d’améliorer l’étude de la variation sur 24h de la sensibilité à l’insuline, l’impact des repas, de l’activité physique, des émotions et du stress.

Partnership

Le Carnot CEA LETI s’attache à valoriser des innovations technologiques de rupture dans les domaines de la santé notamment. Par son investissement, dès 2011, dans la recherche d’une solution d’automatisation du traitement du diabète de type 1, avec le CERITD (Centre d'Études et de Recherches pour l'Intensification du Traitement du Diabète) il a permis de valider le projet qui a abouti à la création de l’entreprise Diabeloop avec laquelle il poursuit le partenariat dans le cadre d’un laboratoire commun dès 2015. Grâce à ses compétences en Data science, le Carnot CEA LETI a contribué à créer un algorithme de contrôle de la délivrance d’insuline en fonction de la mesure continue de glycémie (algorithme de bio-régulation). Il a également participé au développement de l’application qui sert d’interface avec le patient, bénéficiant de sa longue et forte expérience en technologies pour l’IoT.
A l’issue de tests cliniques concluants et de la certification CE, la commercialisation en France et en Europe démarre avec soumission du dossier à la Sécurité Sociale, un déploiement prévu en Allemagne et de premiers contacts avec la FDA aux Etats Unis. L’équipe Diabeloop, qui compte désormais plus de 80 salariés sur Grenoble, Paris et en Allemagne, poursuit l’objectif de gérer les pics glycémiques post-prandiaux, ce qui représente un défi important. L’entreprise a procédé en 2019 à la plus importante levée de fonds européenne en IA. Mais les retours des malades qui expriment par « vous avez changé ma vie » leur satisfaction d’avoir une charge mentale allégée marquent, plus que tout, la réussite d’un partenariat dans la durée.

November 2020

Doctegestio aims to both improve data processing and streamline hospital administration processes through the use of semantic analysis

Partnership Carnot Institute CEA LIST - Doctogestio

The DIM-IA artificial intelligence project tackles the challenge of streamlining codification of  procedures in computerized patient records and speeding up health insurance reimbursements.

Close
Partnership Carnot Institute CEA LIST - Doctogestio

Doctegestio aims to both improve data processing and streamline hospital administration processes through the use of semantic analysis

The DIM-IA artificial intelligence project tackles the challenge of streamlining codification of  procedures in computerized patient records and speeding up health insurance reimbursements.

Supporting Innovation

Doctors must carefully read and transcribe all medical data concerning each of the 7.7 million hospital admissions using a strictly codified nomenclature. This stage is indispensable for patient reimbursement and now serves to populate patient’s shared medical records. Doctegestio, a key stakeholder in healthcare and medical welfare, provides assistance to hospital doctors through a reading and coding solution  based on semantic analysis of natural language that is sufficiently accurate to speed up the outcome and make it more reliable. The DIM-IA project, focusing on hospital medical data and information management departments, combines anonymised databases with artificial intelligence developed by Carnot CEA LIST. The system aims for optimal processing time and coding quality while complying with regulations, thus freeing up high value added medical resources.

The client needs

Doctegestio was created in 2000 and is a major player in healthcare, medical welfare and social and family tourism in France, with 290 establishments and nearly 10,000 employees. The Group’s development strategy is based around strong external growth and highly digitised data management processes. Doctegestio is currently involved in a number of integrated healthcare AI projects that reflect the Group’s commitment to solidarity and upholding the common good. 
Codifying hospital stays requires collation of a vast quantity of data from post-operative reports, hospital admissions and the results of medical tests, etc. In order to ensure complete anonymity, each hospital has an archive of anonymised medical records, based on a unique number without a transcoding table, thus avoiding any identification of patients/visits. The archive is processed using artificial intelligence  based on semantic analysis in qualified medical language. Doctegestio and CEA LIST have conducted a major joint research project to automatically codify medical procedures that monopolise a lot of time and resources . The French national health insurer (CNAM) has already expressed interest in the system as a means of populating patient’s shared medical records.

Partnership

Carnot CEA LIST conducts smart digital systems R&D and has developed solid artificial intelligence expertise. After adapting its semantic analysis algorithms to medical terminology, the Institute has linked its semantic platform to hospital databases managed  by Doctegestio. The system has achieved remarkable performances. The learning process factors in the wide variety of available sources: free [or] unstructured text that is frequently difficult to process. Starting with this unstructured data, AI extracts the relevant information from patient records and classifies it according to the WHO’s ICD-10 statistical classification of diseases and related health problems. This has demonstrated the ability of CEA LIST teams to automatically process the transcription of medical hospital data.  As well as boosting the productivity of the people involved, the system also speeds up the medical billing chain and makes it more secure. 
Following the success of the DIM-IA project, which demonstrates the value and reliability of AI in the healthcare arena, CEA LIST and Doctegestio have set up a joint research lab  and now have their sights set on projects with a nationwide reach.

January 2020

PROTEOR prostheses will now be adapted to everyday living restrictions

Partnership Carnot ARTS - PROTEOR

In addition to facilitating mobility, PROTEOR has teamed up with Carnot ARTS to restore lower limb capacity by reducing restrictions and inconveniences

Close
Partnership Carnot ARTS - PROTEOR

PROTEOR prostheses will now be adapted to everyday living restrictions

In addition to facilitating mobility, PROTEOR has teamed up with Carnot ARTS to restore lower limb capacity by reducing restrictions and inconveniences

Supporting Innovation

Lower-limb amputees now have access to increasingly light prostheses that are much easier to manipulate and may even be adapted to a particular sporting activity. If walking is possible, certain situations require compensating movements on the part of the prosthesis wearer. PROTEOR wanted to get around replacing a missing limb by a passive prosthesis and it harnessed the research of the Georges Charpak Human Biomechanics Institute (IBHGC) to achieve major progress in movement over uneven or unstable ground or when the body is bent over. This research culminated in the creation of a microprocessor-controlled knee-ankle-foot prosthesis, an innovation that has drawn praise from the DGA, the French Defence Procurement Agency.

The client needs

The PROTEOR Group has been meeting the needs of physically handicapped people who require prostheses since it was set up in Burgundy in 1913. It does business in fiercely competitive international markets, notably in Europe, but its “human-first” strategy based on a customised offering has turned it into a key market player. PROTEOR is in constant contact with patients and invests in R&D to deliver reliable and accessible solutions to both individuals and professional customers. This constant quest for improvement highlighted the potential benefits of the close study of prosthesis-wearer walking patterns during an initial partnership with IBHGC and this first phase was rounded out by digital solutions for prosthetic components. PROTEOR and Carnot ARTS have been innovating since 2010 in the whole area of complex movement scenarios. To bolster its position, particularly with major institutional contractors, PROTEOR has renewed its partnership, showcasing the mutual contributions of both organisations.

Partnership

IBHGC is a cross-disciplinary research unit providing expertise in human biomechanics within Carnot ARTS. It is tasked with studying all situations involving injuries or malfunctions, together with the means of preventing, diagnosing and dealing with these situations.
Successive CIFRE PhD agreements have played a big role in developing the modelling base and studying the effects of prosthetics materials on movement by combining an experimental approach with digital modelling.
This cooperation has been in progress since the early 2000s and has enabled Proteor to benefit from cutting-edge research within a relationship based on mutual trust and exchange. The diversity of patient case studies, their evolution over time and the durability of ties with PROTEOR have facilitated the deployment of embedded technologies in a product that has been awarded a prize by the French Ministry of Defence.
PROTEOR continues to focus on customisation and research into adapting to everyday living restrictions and the quality of the fit in order to secure its future development.

October 2019

French Group Lebronze alloys commit to the health sector with new high-performance copper alloy

Partnership MICA Carnot Institute - Lebronze alloys

The MICA Carnot Institute showed and quantified scientifically the bactericidal properties of the already marketed Steriall range.

Close
Partnership MICA Carnot Institute - Lebronze alloys

French Group Lebronze alloys commit to the health sector with new high-performance copper alloy

The MICA Carnot Institute showed and quantified scientifically the bactericidal properties of the already marketed Steriall range.

Supporting Innovation

Lebronze alloys have been known for quite some time for using copper, a metal acknowledged to be showing a very strong micro-organism resistance, in particular against pathogenic bacteria.
However, the effects of a real activity in terms of sanitation and health protection obtained through quantitative information using sound and thorough scientific methods must be shown to both companies and the general public.

The research teams wanted to check and evaluate in real-life situations the benefits of door equipments, handles, handrails, railings as well as thrust plates required by very demanding healthcare establishments such as: hospitals, long-term care nursing homes ()…
Whereas stainless steel, widely used in door handles, remains almost inert, the French-manufactured Steriall alloy is highly effective. It has indeed proven to reduce the risk of infection through direct contact.

copyright : Steriall

The client needs

Lebronze alloys is a key player on the metal industry.  Thanks to strong growth the company invests each year several millions of Euros in R&D.The already Cu+-labelled Steriall product line has been on the market since 2012.

Nevertheless, the laboratory wanted to explore without bias the anti-bacterial qualities of the Lebronze alloy mixed metal so as to present convincing elements of the copper effects upon pathogenic factors.
Following a very first positive study with the MICA Carnot Institute in 2014, the company has renewed its partnership to measure the impact of the products in real usage situations.
The MICA Carnot Institute has put forward a two-stage evaluation protocol validated through both in vitro and in situ assessments.
BIOS* laboratory’s expertise in microbiology has enabled to bring about the much needed deliverables expected from the teams of the Eastern France-based foundry and supplying transformer.
Hence asserting Lebronze alloys’ ambition to value the beneficial aspects of their natural copper alloys for overall human health.

* Biomatériaux et inflammation en site osseux (Biomaterials and Inflammation in Bone Site)

 

Partnership

The MICA Carnot Institute supports innovation through its work on functional materials in the health, building and transport sectors. The Institute integrates 9 research laboratories and 8 technological resources centres based in the ‘Grand Est (Eastern France)’ region. BIOS first determined the given time necessary to kill opportunistic pathogenic agents in contact with various copper alloy touch surfaces.

The researchers then compared the microbial populations of a variety of handle types inside 5 nursing homes.
The study has confirmed that the examined bacteria have been found to survive for several months on a said support, but 90% did not by simple alloy (Steriall series) contact.
The taking methodology used made it possible for Lebronze alloys to move forward in terms of strategy against microbial resistance. It is also at the origin of a draft standard with the French Standardization Association (Association Française de Normalisation, AFNOR) on the measurement of anti-microbial activities of non-porous surfaces.

December 2018

Fluigent provides laboratories with effective and reliable precision analyses techniques at the micron and the nanometre length-scale

Partnership M.I.N.E.S and Fluigent

To gain a larger share of such very dynamic market and increase competitiveness, Fluigent, a pioneer of microfluidics, features the  algorithms developed by the M.I.N.E.S Carnot Institute in terms of innovation.

Close
Partnership M.I.N.E.S and Fluigent

Fluigent provides laboratories with effective and reliable precision analyses techniques at the micron and the nanometre length-scale

To gain a larger share of such very dynamic market and increase competitiveness, Fluigent, a pioneer of microfluidics, features the  algorithms developed by the M.I.N.E.S Carnot Institute in terms of innovation.

Supporting Innovation

Microfluidics ensures that vast numbers of samples can be processed very quickly to the benefit of the many laboratories involved in various fields such as biology, medicine, pharmacology…
Due to the techniques used, the automated manipulation and the quantities applied are helping to lower the cost of the undertaken laboratory analysis.
On the one hand, Fluigent stands out by its own disruptive technology which incorporates powerful algorithms. On the other hand, by its dedication to integrating solutions ensuring a steady microfluidic flow and a sophisticated management of complex fluidic systems.

FRCM* products and EZ™ Flow developed in partnership with the M.I.N.E.S Carnot Institute are much appreciated by their users and forecast the efficient, reliable, economical with-a-strong-adaptation-capacity laboratory of the future.

*Flow rate control module

The client needs

As of 2006, Fluigent has verified that the analysis of micro samples of fluids circulating in channels etched on a glass or plastic plate opens up a new era of instrumentation.
Yet, this technology dictates a complete mastery of the fluid circulation through the channels. Fluigent is then primarily driven by reliability and miniaturisation considerations. Its teams think out flow control systems that may be put together to build upon request tools able to be rapidly operational readiness without requiring a long calibration step.
The French-based SME has been partnering from 2012 onwards with the Centre for Systems and Control (CAS-MINES ParisTech) of the Carnot M.I.N.E.S institute.
This partnership materialises very quickly with the launch of the FRCM software (2013), then the Flow EZTM (2017) modules, which significantly contribute to the steady revenue growth providing a strong competitive edge over the competitors.

Partnership

The M.I.N.E.S Carnot Institute** aims to eliminate scientific barriers to allow for innovative technology development with a strong socio-economic impact.
The teams have taken advantage of their 15 years of work in control theory and succeeded in improving performance significantly. The contribution involves optimising the control of miniature valves thanks to embedded algorithms continuously monitoring flows in real time.
The partnership has staunchly upheld the solid principles of independence while safeguarding Fluigent industrial property rights, as well as its closeness to end-users’ applications.
Being involved in the design of the Flow EZTM module architecture since the beginning, the team led by Nicolas PETIT has contributed to the strengthened leadership of the French firm of 30. Fluigent pursues its strong growth and global expansion in more than 40 countries.

**Innovative Methods for Business and Society

June 2018

While the dental implant market is bursting, Anthogyr, in co-operation with Ingénierie@Lyon, innovates to improve efficiency

Partnership Ingénierie@lyon - Anthogyr

With a better control of the behaviour of new zirconia-based composite features Anthogyr has been able to improve the stability of its ceramics and unlock innovation potential to gain a relevant position at an international level.

Close
Partnership Ingénierie@lyon - Anthogyr

While the dental implant market is bursting, Anthogyr, in co-operation with Ingénierie@Lyon, innovates to improve efficiency

With a better control of the behaviour of new zirconia-based composite features Anthogyr has been able to improve the stability of its ceramics and unlock innovation potential to gain a relevant position at an international level.

Supporting Innovation

Zirconium dioxide (ZrO2) known as zirconia has been actively used in biomedical contexts, notably the dental sector, for about 15 years, where its use effectively meets the needs of patients in terms of safety and aesthetics.
Through further improvements of both the composition and the manufacturing technique of zirconia-based ceramics, Anthogyr hope to gain more security and more market share.
The innovation consists in extending the implant’s behaviour over time without degradation products combined with a production on an industrial scale.
Already established in China and Russia, Anthogyr faces fierce competition. Its ability to offer a range of superior products at an affordable price corresponds to its ‘Prime Mover in Implantology’ strategy.

Copyright : Anthogyr

The client needs

Anthogyr, an intermediate-sized enterprise established in the French Alps, wants to effectively meet the challenge of ever-increasing demand in implants at a global level.
For that matter, Anthogyr has engaged in the design, manufacturing and distribution of an extensive range of products for the oral health professionals.
For some products, the enterprise uses zirconia recognised for its biocompatibility, toughness and whiteness properties.
By using a high-quality zirconia powder, Anthogyr possesses complete mastery of the entire production chain to provide supply of products well-suited to complex prostheses in different degrees of translucency and colour shades.
In 2015, the partnership with Ingenierie @ Lyon Carnot Institute is given concrete form with the launching of a common laboratory with Mateis, a Material Science Laboratory based in Lyon. The establishment of such common laboratory has triggered a considerable step towards increasing resistance to water and corrosion of implants (biofluids) through doped cerium rather than yttrium.
Research on the manufacturing process on an industrial scale was carried out in parallel with the development of this new range of composite ceramic.

Partnership

The MATEIS’ team is part of the Ingenierie@Lyon Carnot Institute, a Material Science specialist lab centred on a research approach that blends chemical, physical and mechanical simulations applied to medicine, transport and energy mechanisms.
The lab aims to reveal, through experimentation and modelling, the technical relationships between the recipe, the microstructure and the physical properties of both metals and polymer-derived ceramics and composites.
Internationally recognized for the commitment and high standard of the work of its researchers, it has been able to boost Anthogyr’s innovative capacity from a technological perspective as well as in terms of economics.
Within the context of the LEAD* common Lab, a Speciality Appliances Dental/Orthodontic Laboratory, Mateis and Anthogyr have pooled their expertise to acquire the knowledge and skills of information and technologies necessary, in additive manufacturing especially, and a renewed vision for the approach to dental implant therapies in the future.
Worth more than EUR 46 million, Anthogyr employs more than 330 people in France and 420 globally, and devotes 8% of its revenue to R&D. For Anthogyr the R&D partnership with the Carnot Institute has become a key component in stepping up growth through innovation of a complete range of associated products and services.

*LEAD = Laboratoire d’Excellence en Application Dentaire

March 2018

Carnot ICÉEL contributes to Crossject successful completion of a specific needle-less syringe

Partnership with ICÉEL Carnot Institute and Crossject

Crossject has reached its intended goal of providing safe medical injection without the use of a needle in a format adapted to the needs of both the professionals and the patients.

Close
Partnership with ICÉEL Carnot Institute and Crossject

Carnot ICÉEL contributes to Crossject successful completion of a specific needle-less syringe

Crossject has reached its intended goal of providing safe medical injection without the use of a needle in a format adapted to the needs of both the professionals and the patients.

Supporting Innovation

Crossject aspires to make the injection of medical products at a more reliable pace with a single button press using NFIT (Needle-free injection technology). Indeed, the needle-free procedure minimises the stress induced by the patient as well as the unpredictable effects upon the medical injection considerably. ZENEO®’s commercialisation move comes after several years of research in co-operation with doctors and patients. The simple ‘single-use’ device guarantees the correct quantity of products in an ideal environment. The unique highly specialised expertise acquired has made it possible for Crossject to become a key player in his field. The SME undeniably provides enhancements that can help improve the self-injection process when caring for chronically ill persons and/or in an emergency setting.

The client needs

Crossject has been demonstrating the validity of its concept in 2005 since day one, when conducting the first controlled clinical evaluation of a specific influenza vaccine. Initially, concrete steps had to be taken in terms of ergonomics and regulation of injection quantity. The device was designed to allow adaptation to different fluid injection viscosity volumes according to the depth desired, whether intradermal, subcutaneous or intramuscular.
However, the conventional methods used to validate the device effectiveness fell short of expectations. According to statements by Patrick Alexandre, the Crossject’s CEO, the partnership with a team of the ICÉEL Carnot Institute*, a Fluid Dynamics specialist, enabled to explore solutions very far apart from the traditional reasoning.
For Crossject, the TJFU** Laboratory, a unit of Carnot ICÉEL, has drawn on its experience in modelling and implementation of pulsed microjet nozzles to conceive an innovative injection duct A key component of the delivery device, it is the subject of numerous patents placing Crossject in a situation of authority over the competition.

* ICÉEL : Institut Carnot Énergie et Environnement en Lorraine
** Technical centre specialising in abrasive water jet destined to the cutting of metal parts

***  Technological Resource Centre

Partnership

The ICÉEL Carnot Institute brings together 22 laboratories. Its R&D spectrum allows the backing of projects with a significant social impact in areas relating to energy and environmental sustainability.
The Institute acting as the R&D partner of a majority of the largest manufacturers, as well as SME’s matching Crossject’s profile, has helped the latter to innovate by breaking with normal practice. As a pulsed microjet specialist, TJFU’s CRT***, has been a 10-20% hydrodynamic efficiency saver for the injector duct using an innovative geometry optimisation. Abdel Tazibt, a TJFU CRT researcher, underscores the importance of such contributions for the successful improvement of ZENEO® in terms of effectiveness.
To further enhance the ZENEO®-designed syringe’s flexibility and robustness and reduce costs, co-operation is being continued and extended beyond the common patent application.
5 out of 7 products to be used during emergency and disaster situations are currently awaiting regulatory approval.
In 2017, ZENEO® has scooped the Janus Award, in the Prospective category, acknowledging the impact of user behaviour, the introduction of newer applications and the emergence of a new economy.

February 2018

The French solution to treat obesity without surgery arises from a partnership Carnot

Partnership Cetim Carnot Institute - Horuscare

Start-up Horuscare considers clinical trials of alternative innovative solution to bariatric surgery for 2017 agenda.

Close
Partnership Cetim Carnot Institute - Horuscare

The French solution to treat obesity without surgery arises from a partnership Carnot

Start-up Horuscare considers clinical trials of alternative innovative solution to bariatric surgery for 2017 agenda.

Supporting Innovation

Slowing passage into the bloodstream of essential nutrients so as to facilitate significant weight loss! Such is the tenet of Horuscare’s ‘Reborn’ medical device. A 60-cm titanium / silicone tube that is inserted into the duodenum during an  endoscopic by high channel non-surgical procedure. Once the tube is in place, the outer membrane prevent fats and sugar from quickly seeping into the bloodstream. The system effectiveness in particular lies in its capacity to seal off the supply of nutrients, at the same time assess organic stability.

The client needs

Horuscare was born out of the conviction of Jean-Michel Verd, the founder of the company, that existing obesity treatment approaches needed to be re-thought. Both mechanical and medical expertises have been necessary to determine the relevant technical base to guarantee stability and reliability of the system after implementation. The first step required formalising a set of constraints in accordance with very strict specifications imposing that no hook cause wounds or infections.  The device placement was however recognised essential to avert migration and subsequent intestinal obstruction due to contractions. In view of such procedure, long-term simulator testing was performed to allow validation of the 60-cm tube length hypothesis based on the original anatomical shape of the intestine (anchoring the final 3D-position of the ligament of Treitz at 180 degrees)

Partnership

Assistance has been provided as needed to Horuscare by CETIM Carnot Institute at Saint-Étienne for the development of the medical device. After specifications were completed several alternatives assessments have been devised. Hence stent– which is already used in cardiology - as the chosen solution. The waterproof membrane structure is supported by the stent which is held in position without hooks. Consequently, the device and unique test bench were jointly developed by CETIM and Horuscare. Such bench is used by both Radwan Kassir, MD. at Saint-Étienne University College Hospital, and Horuscare to determine the proof-of-concept in vitro study with a prototype. Beyond the patenting, Horuscare is presently involved with animal-based (in vivo) testings, at the same time seeking adequate funding of clinical trials applied to the human body. This innovation enriches the offer of not surgical therapy and aims at a multi-million euro mainly export market.

October 2016

From the treatment of blindness to Super Bowl

Partnership Voir et Entendre Carnot Institute - Atis

Atis, from Research to global industrial success.

Close
Partnership Voir et Entendre Carnot Institute - Atis

From the treatment of blindness to Super Bowl

Atis, from Research to global industrial success.

Supporting Innovation

ATIS is a camera whose system core works in a similar way to the eye retina. The bio-inspired vision sensor operates in an asynchronous mode on a stream of per-pixel incoming events rather than displaying conventional split-action movement by superimposition of successive images. The sensor performance in terms of data acquisition, encryption and energy consumption makes it an essential and unique choice for applications requiring capture of real-time data.

The client needs

This technology was first applied to respond to the specific needs related to the development of bionic vision systems (artificial retina). Such systems require an expedite processing of images associated with encoded information adapted to the specific retinal and cortical features.

The IRIS2* device, which is going through a clinical assessment, is currently being developed by Pixium Vision, a leading player in the treatment of blindness. The device, combining both an ATIS sensor and a retina implant, allows observed subjects with retinitis pigmentosa (RP) to perceive certain patterns of light and some shapes of objects and acquire a greater degree of autonomy in their day-to-day lives.

Beyond the more constant  medical activity, ATIS high potential was the key reason for setting up French spin-off Chronocam, to further develop its use across all image sensor markets (haulage, robotics, security, video games), and in the not too distant future improve instant replays at major sporting events such as the Super Bowl!

*Intelligent retinal implant system, second generation

Partnership

The ‘Voir et Entendre’ Carnot Institute is one of the leading integrated Eye Research centresin Europe. It was in this Institute that the team of researchers and mathematicians designed the sensors and algorithms in co-operation with Pixium Vision. On top of this, the Institute is concurrently working in close collaboration with Chronocam. These various exchanges show the Carnot Institute’s ability to effectively integrate into the economic and industrial realities of innovative enterprises.

  

July 2016

With the serious game Toap Run Genious becomes an actor of silver economy

Partnership ICM Carnot Institute - Groupe Genious

The Genious-ICM Carnot resulting partnership initiative stands out for its therapeutic software excellence.

Close
Partnership ICM Carnot Institute - Groupe Genious

With the serious game Toap Run Genious becomes an actor of silver economy

The Genious-ICM Carnot resulting partnership initiative stands out for its therapeutic software excellence.

Supporting Innovation

Thanks to the joint efforts of computer-games specialists, neuroscientists [OU brain researchers] and clinicians the use of gaming applications [OU of serious games] as a practical tool in healthcare is now very much a reality. The growing aging population means looking at new mechanisms to prevent and manage neurological disorders from a mixture of sources (Alzheimer’s disease, stroke…). The designed ‘Toap Run’ software intented for people suffering from Parkinson’s disease combines digital creativity and a high level of scientific rigour. The rapidly developing healthcare industry was very much in need of such forerunner with very effective – verified and calibrated - innovative solutions. As of October 2016 the Toap Run serious game will be freely available to health care professionals once the subsequent clinical phase has been validated.

The client needs

Since 1983, the small and medium-sized Paris area-based Genious Group of 200 employees, with branches in Montpellier and Rennes, has developed the skills and expertise needed in the fields e-learning, mobile data and serious games. As an e-health contributor, the IT services provider has wanted to improve mobility of all patients with Parkinson’s disease. Furthermore the entire solution had to be cost-effective and scalable so as to provide helpful reference to caregivers to track symptom assessment. To validate such approach Genious Group had to ensure continuity of scientific support for the project and evaluate its possible use in real-life settings.

Partnership

The ICM Carnot Institute is conducting active brain and spinal cord research at Pitié-Salpêtrière Hospital in Paris. Consequently, both the researchers and clinical neurosciences experts have collaborated with Genious on the Toap Run project. As a result, progress in primary health care affecting therapists as well as patients has permitted to allow Genious to be recognised among one of the best digital gold diggers. In addition, Toap Run has been selected as a potential successful candidate as part of the WorldWide Innovation Challenge 2030. Beyond general availability for the software, the desired partnership took on concrete form also with the establishment of a shared lab called BRAIN e-NOVATION

June 2016
Other sectors Healthcare & Sport